Last reviewed · How we verify
Kengreal (CANGRELOR)
Kengreal blocks the action of ADP on platelets, preventing platelet activation and aggregation.
Kengreal (Cangrelor) is a P2Y12 platelet inhibitor, a small molecule drug developed by Medicines Co and currently owned by Chiesi. It targets the P2Y12 purinoceptor, a receptor on platelets that plays a key role in blood clotting. Kengreal is FDA-approved for use in percutaneous coronary intervention (PCI) and works by blocking the action of adenosine diphosphate (ADP) on platelets, thereby preventing platelet activation and aggregation. As of 2023, Kengreal is still patented, but generic manufacturers are available. Key safety considerations include bleeding risks and potential interactions with other medications.
At a glance
| Generic name | CANGRELOR |
|---|---|
| Sponsor | Chiesi |
| Drug class | P2Y12 Platelet Inhibitor [EPC] |
| Target | P2Y purinoceptor 12 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2015 |
| Annual revenue | 200 |
Mechanism of action
Cangrelor is direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation.
Approved indications
- Percutaneous coronary intervention
Common side effects
- Bleeding
- Dyspnea
- Decreased renal function
- Hypersensitivity
- Coronary artery dissection
- Coronary artery perforation
- Anaphylactic reactions
- Anaphylactic shock
- Bronchospasm
- Angioedema
- Stridor
- Worsening renal function
Key clinical trials
- REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (PHASE3)
- ARCANGELO (itAlian pRospective Study on CANGrELOr)
- Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients
- The Bridging Antiplatelet Therapy With Cangrelor 2 Study (PHASE4)
- Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial (PHASE3)
- Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)
- Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
- The Effect of IV Cangrelor and Oral Ticagrelor Study (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kengreal CI brief — competitive landscape report
- Kengreal updates RSS · CI watch RSS
- Chiesi portfolio CI